• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

ASCO 2025: Fixed-Duration Treatment Emerges as Future of Multiple Myeloma Management

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma. Read More

Neoadjuvant Osimertinib With or Without Chemotherapy Improves Response in Resectable EGFRm NSCLC

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles Results from the NeoADAURA trial demonstrate the sustained efficacy of osimertinib in patients with epidermal growth factor receptor-mutated (EGFRm) non-small-cell lung cancer (NSCLC). Read More

Fixed-Duration Ibrutinib Plus Venetoclax Shows Long-Term Efficacy in First-Line CLL/SLL Treatment

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles Ibrutinib plus venetoclax shows promising long-term survival rates, including those who are considered high risk. Read More

GLP-1 Receptor Agonists and FGF21 Analogs May Be Key Treatments for MASH-Related Cirrhosis

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles New treatments for metabolic dysfunction-associated steatohepatitis (MASH)–related cirrhosis address unique challenges in drug development. Read More

IDSA Guideline Recommendations: Treating Multi-Drug Resistant and Difficult to Treat Resistant P. aeruginosa

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles Infectious Disease Society of America guidance defines difficult-to-treat resistant Pseudomonas aeruginosa as resistance to all first-line agents. Read More

ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC). Read More
« Older Entries
Next Entries »

Recent Content

  • Op-Ed: Expand Patient Choice to Lower Medication Costs
  • Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
  • Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics
  • Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
  • SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity
  • GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes
  • The Invisibility of Blood Cancers to Others
  • Op-Ed: Prescribing Cascade Is Avoidable—If We Empower Pharmacists to Intervene
  • MVdeltaC Earns Orphan Drug Status for Pleural Mesothelioma
  • Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT